George Farmer
Stock Analyst at Scotiabank
(3.81)
# 1,077
Out of 4,479 analysts
33
Total ratings
42.11%
Success rate
14.12%
Average return
Main Sectors:
Top Industries:
21 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Maintains: Sector Outperform | $41 → $21 | $4.42 | +375.11% | 2 | Jun 7, 2024 | |
| JANX Janux Therapeutics | Initiates: Sector Perform | $47 | $41.72 | +12.66% | 1 | May 30, 2024 | |
| ADAP Adaptimmune Therapeutics | Initiates: Sector Outperform | $3.15 | $1.05 | +200.00% | 1 | May 30, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Sector Perform | $83 → $85 | $82.13 | +3.49% | 3 | Apr 25, 2024 | |
| SAGE Sage Therapeutics | Maintains: Sector Outperform | $34 → $19 | $11.03 | +72.26% | 2 | Apr 18, 2024 | |
| LEGN Legend Biotech | Upgrades: Sector Outperform | $65 | $46.02 | +41.24% | 2 | Apr 17, 2024 | |
| ARGX argenx SE | Maintains: Sector Perform | $402 → $408 | $434.22 | -6.04% | 4 | Mar 26, 2024 | |
| ABSI Absci | Initiates: Sector Outperform | $13 | $3.01 | +331.89% | 1 | Mar 14, 2024 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Sector Outperform | $35 | $20.58 | +70.07% | 2 | Mar 14, 2024 | |
| TPST Tempest Therapeutics | Initiates: Sector Outperform | $13 | $2.14 | +507.48% | 2 | Mar 14, 2024 | |
| SNDX Syndax Pharmaceuticals | Downgrades: Sector Perform | $36 → $23 | $21.53 | +6.83% | 2 | Jan 31, 2024 | |
| ACLX Arcellx | Initiates: Sector Outperform | $66 | $53.60 | +23.13% | 1 | Dec 19, 2023 | |
| KURA Kura Oncology | Initiates: Sector Perform | $11 | $21.20 | -50.47% | 1 | Jul 27, 2023 | |
| BIIB Biogen | Initiates: Sector Outperform | $327 | $231.77 | +41.09% | 1 | Jul 27, 2023 | |
| AURA Aura Biosciences | Initiates: Sector Outperform | $23 | $7.37 | +212.08% | 1 | Jul 27, 2023 | |
| MRNA Moderna | Downgrades: Market Perform | n/a | $115.95 | - | 1 | Nov 17, 2020 | |
| CCCC C4 Therapeutics | Initiates: Outperform | n/a | $4.85 | - | 1 | Oct 27, 2020 | |
| IMUX Immunic | Initiates: Outperform | n/a | $1.12 | - | 1 | Jul 20, 2020 | |
| BPMC Blueprint Medicines | Upgrades: Outperform | n/a | $109.18 | - | 2 | Mar 17, 2020 | |
| EXEL Exelixis | Maintains: Market Perform | n/a | $22.25 | - | 1 | Feb 26, 2020 | |
| INCY Incyte | Maintains: Market Perform | n/a | $60.87 | - | 1 | Jan 3, 2020 |
Biomea Fusion
Jun 7, 2024
Maintains: Sector Outperform
Price Target: $41 → $21
Current: $4.42
Upside: +375.11%
Janux Therapeutics
May 30, 2024
Initiates: Sector Perform
Price Target: $47
Current: $41.72
Upside: +12.66%
Adaptimmune Therapeutics
May 30, 2024
Initiates: Sector Outperform
Price Target: $3.15
Current: $1.05
Upside: +200.00%
BioMarin Pharmaceutical
Apr 25, 2024
Maintains: Sector Perform
Price Target: $83 → $85
Current: $82.13
Upside: +3.49%
Sage Therapeutics
Apr 18, 2024
Maintains: Sector Outperform
Price Target: $34 → $19
Current: $11.03
Upside: +72.26%
Legend Biotech
Apr 17, 2024
Upgrades: Sector Outperform
Price Target: $65
Current: $46.02
Upside: +41.24%
argenx SE
Mar 26, 2024
Maintains: Sector Perform
Price Target: $402 → $408
Current: $434.22
Upside: -6.04%
Absci
Mar 14, 2024
Initiates: Sector Outperform
Price Target: $13
Current: $3.01
Upside: +331.89%
NewAmsterdam Pharma Company
Mar 14, 2024
Initiates: Sector Outperform
Price Target: $35
Current: $20.58
Upside: +70.07%
Tempest Therapeutics
Mar 14, 2024
Initiates: Sector Outperform
Price Target: $13
Current: $2.14
Upside: +507.48%
Syndax Pharmaceuticals
Jan 31, 2024
Downgrades: Sector Perform
Price Target: $36 → $23
Current: $21.53
Upside: +6.83%
Arcellx
Dec 19, 2023
Initiates: Sector Outperform
Price Target: $66
Current: $53.60
Upside: +23.13%
Kura Oncology
Jul 27, 2023
Initiates: Sector Perform
Price Target: $11
Current: $21.20
Upside: -50.47%
Biogen
Jul 27, 2023
Initiates: Sector Outperform
Price Target: $327
Current: $231.77
Upside: +41.09%
Aura Biosciences
Jul 27, 2023
Initiates: Sector Outperform
Price Target: $23
Current: $7.37
Upside: +212.08%
Moderna
Nov 17, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $115.95
Upside: -
C4 Therapeutics
Oct 27, 2020
Initiates: Outperform
Price Target: n/a
Current: $4.85
Upside: -
Immunic
Jul 20, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.12
Upside: -
Blueprint Medicines
Mar 17, 2020
Upgrades: Outperform
Price Target: n/a
Current: $109.18
Upside: -
Exelixis
Feb 26, 2020
Maintains: Market Perform
Price Target: n/a
Current: $22.25
Upside: -
Incyte
Jan 3, 2020
Maintains: Market Perform
Price Target: n/a
Current: $60.87
Upside: -